Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals
Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Christoph Wanner(Universitätsklinikum Würzburg), Dominik Steubl(Boehringer Ingelheim (Germany)), David C. Wheeler(University College London), Amelie Elsaesser(Boehringer Ingelheim (Germany)), Ivana Ritter(Boehringer Ingelheim (Germany)), Sibylle J. Hauske(Heidelberg University), Kent Doi(University of Tokyo Hospital)
Cited by 3
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k